Navigation Links
YM BioSciences provides update on AeroLEF(TM) clinical development program
Date:1/17/2008

MISSISSAUGA, ON, Jan. 17 /PRNewswire-FirstCall/ - YM BioSciences Inc. (AMEX: YMI, TSX: YM, AIM: YMBA), an oncology company that identifies, develops and commercializes differentiated products for patients worldwide, today announced that it has received a letter from the U.S. Food and Drug Administration (FDA) informing the Company that the Phase II Acute Pain Study (AP5) of AeroLEF(TM) for which FDA clearance was announced on June 27, 2007, upon re-review of data from the IND submission, has been placed on clinical hold. The FDA has requested additional safety information on specific patients in previous clinical studies. The additional requested data is limited to a small group of patients that experienced oxygen desaturation, a class effect of opioids including fentanyl. The Company will conduct a subgroup analysis on these patients. To date, no patients have been dosed in the US AP5 study and there are no other clinical trials involving AeroLEF(TM) currently ongoing.

"We are confident that we can provide the information the FDA has requested in a timely manner," said David Allan, Chairman and CEO of YM BioSciences. "We appreciate that the FDA has to ensure that any risk to patients during clinical trials is minimized and we understand their caution with opioid-based therapeutics."

Dr. Diana Pliura, Executive Vice President, AeroLEF(TM) added, "Data reported in May 2007 from our successful randomized Phase 2b trial demonstrated that patients had a statistical and clinical benefit from AeroLEF(TM). We remain strongly committed to the clinical development of this unique product."

YM BioSciences also reported that it held its scheduled End-of-Phase 2 (EoP2) meeting with the FDA on January 16, 2007 as planned.

YM
'/>"/>

SOURCE YM BioSciences Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
2. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
3. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
4. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
5. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
6. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
7. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007
8. Magellan Biosciences Names Steven E. Diamond, PhD, Chief Scientific Officer
9. Pressure BioSciences, Inc. Issued First Patent in Canada
10. Neurocrine Biosciences to Present at the BioCentury: Newsmakers in the Biotech Industry Conference
11. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)... July 6, 2015  Approximately 1% of the population ... their chromosomes. These individuals are three times more likely ... in one of the nation,s leading medical journals by ... Canada.  Photo - http://photos.prnewswire.com/prnh/20150706/230685 ... (HHV-6) causes roseola (also known as "sixth disease") and ...
(Date:7/6/2015)... ... July 06, 2015 , ... Discovery of new biomarkers ... key drivers of the global molecular diagnostics market. BCC Research reveals in its ... new companion diagnostic tests will increase demand for inexpensive and accurate tests for ...
(Date:7/6/2015)... , July 6, 2015  Viveve Medical, Inc. ("Viveve") (OTCQB: VIVMF), ... Patricia Scheller , Viveve,s Chief Executive Officer, and Scott ... VirtualInvestorConferences.com on July 9, 2015. , , , ... , , , TIME:     , , , ... , , , http://tinyurl.com/viveve   , ...
(Date:7/6/2015)... July 6, 2015 ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") ... agreement with Novella Clinical (Novella), to conduct ... with newly diagnosed glioblastoma. Novella is a full-service, global ... small to mid-sized oncology companies. The ICT-107 phase 3 ... US, Europe and ...
Breaking Biology Technology:Inherited Herpes Virus Increases the Risk of Angina Reports HHV-6 Foundation 2Inherited Herpes Virus Increases the Risk of Angina Reports HHV-6 Foundation 3Demand for Personalized Medicine, Innovative Molecular Diagnostic Tests Spurring Big Growth, According to BCC Research 2Demand for Personalized Medicine, Innovative Molecular Diagnostic Tests Spurring Big Growth, According to BCC Research 3Viveve to Webcast Live at VirtualInvestorConferences.com 2Viveve to Webcast Live at VirtualInvestorConferences.com 3ImmunoCellular Therapeutics Establishes Agreement with Novella Clinical to Conduct ICT-107 Phase 3 Registration Trial in Glioblastoma 2
... Nokia,s new website, which provides innovative ways to interact with thought ... , ... San Francisco, CA (PRWEB) February 12, 2009 -- ... genetic testing service 23andme, says that as we further our understanding ...
... OriGene Technologies, Inc. ("OriGene") today announced it ... private equity financing. With this financing, OriGene completed ... Shenzhen P&A Biotech, a manufacturer and provider of ... this acquisition OriGene completes the establishment of its ...
... for the control of parasites in agriculture and medicine, today announced that ... will further its efforts to create solutions for one of the major ... ... (PREWB) February 11, 2009 -- Biotechnology firm Divergence, Inc., a world leader ...
Cached Biology Technology:Famed IT Investor and Director of 23andme Esther Dyson Identifies on IdeasProject.com Genetic Information as an Extremely Disruptive Force 2Famed IT Investor and Director of 23andme Esther Dyson Identifies on IdeasProject.com Genetic Information as an Extremely Disruptive Force 3OriGene Technologies, Inc. Establishes High Throughput Monoclonal Antibody Production Outsourcing Center in China 2Divergence Raises $11.8 Million in Series C Financing 2Divergence Raises $11.8 Million in Series C Financing 3
(Date:6/24/2015)... 2015 Biometry authentication provider KeyLemon today ... solution one face in. Logo ... face in, entering the expanding biometric authentication market ... biometric answer to the password problem. With advanced ... with KeyLemon, one face in allows users to ...
(Date:6/23/2015)... Fla. , June 23, 2015 /PRNewswire/ ... management and authentication solutions, today announced enhanced functionality ... multi-factor authentication solution.  The enhancements build on ... of the DigitalPersona Altus platform and provide ... compatibility. In today,s environment of ...
(Date:6/17/2015)... and HILDEN, Germany , June 17, 2015 ... Frankfurt Prime Standard: QIA) today launched new Investigator ® ... laboratories in the United States . The ... analyze multiple key genomic markers (short tandem repeats or STRs) ... Sensor to evaluate the quality of DNA in each sample, ...
Breaking Biology News(10 mins):KeyLemon Announces Partnership With Biometric Password Solution onefacein 2Crossmatch Releases Enhanced DigitalPersona Altus Advanced Authentication Functionality 2QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 2QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 3QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 4QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 5
... at Memorial Sloan-Kettering Cancer Center (MSKCC) have shown for ... blood disorders may be inherited. Their research, published online ... genetic sequence abnormality that enhances the likelihood of acquiring ... diseases. The investigators carried out a genome-wide study ...
... (NIEHS), part of the National Institutes of Health (NIH), ... of Toxicology (SOT) meeting in Baltimore, Md. Scientists from ... NIEHS administers, as well as their grantees and collaborators, ... the field of toxicology. Why: The SOT Annual Meeting ...
... researchers at Kansas State,University, with collaboration from Epitopix ... against E. coli O157 in beef ... focus on the post-harvest food safety,aspect, whether it,s ... Thomson of,K-State,s College of Veterinary Medicine. Thomson is ...
Cached Biology News:Hear about emerging trends in toxicology research 2K-State researchers help Epitopix license the United States' first E. coli O157 vaccine for cattle 2